---
title: "VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296932909.md"
description: "VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase"
datetime: "2026-08-25T15:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296932909.md)
  - [en](https://longbridge.com/en/news/296932909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296932909.md)
generator: "portal-rs"
---

# VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase


### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650](https://longbridge.com/en/news/297556855.md)
- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows](https://longbridge.com/en/news/297849557.md)
- [Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform](https://longbridge.com/en/news/297782178.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**